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Background: Aberrant activation of the Wnt/β-catenin signaling pathway is an important factor in the
development of nasopharyngeal carcinoma (NPC). Previous studies have demonstrated that the developmental
gene sex-determining region Y (SRY)-box 1 (SOX1) inhibits cervical and liver tumorigenesis by interfering with the
Wnt/β-catenin signaling pathway. However, the role of SOX1 in NPC remains unclear. This study investigates the
function of SOX1 in NPC pathogenesis.
Results: Down-regulation of SOX1 was detected in NPC cell lines and tissues. Besides, quantitative methylation-specific
polymerase chain reaction revealed that SOX1 promoter was hypermethylated in NPC cell lines. Ectopic expression of
SOX1 in NPC cells suppressed colony formation, proliferation and migration in vitro and impaired tumor growth in
nude mice. Restoration of SOX1 expression significantly reduced epithelial-mesenchymal transition, enhanced cell
differentiation and induced cellular senescence. Conversely, transient knockdown of SOX1 by siRNA in these cells
partially restored cell proliferation and colony formation. Notably, SOX1 was found to physically interact with β-catenin
and reduce its expression independent of proteasomal activity, leading to inhibition of Wnt/β-catenin signaling
and decreased expression of downstream target genes.
Conclusions: SOX1 decreases the expression of β-catenin in a proteasome-independent manner and reverses
the malignant phenotype in NPC cells.
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Nasopharyngeal carcinoma (NPC) is the most common
head and neck cancer in southern China, Southeast Asia,
the Arctic and the middle/northern regions of Africa.
The incidence of NPC in southern China is approxi-
mately 25–50 per 100,000 persons each year, which is
100-fold higher than that in Western countries [1-3].
The poor clinical outcome of NPC is largely attributable
to resistance to therapies and metastasis [4]. Therefore,
new strategies for safer and more effective treatment are
urgently needed [5]. The molecular mechanisms under-
lying the pathogenesis of NPC are incompletely defined,* Correspondence: liuq9@mail.sysu.edu.cn
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The family of sex-determining region Y (SRY)-box (SOX)
proteins is a group of transcription factors that contain
a highly conserved high-mobility group (HMG) DNA-
binding domain. SOX family members play crucial roles
in both embryonic and postnatal development and in stem
cell regulation [6-8]. Moreover, several members of the
SOX family have been implicated in cancer development
[9-14]. For example, SOX10 facilitates the formation of a
stable SOX10/T-cell factor (TCF)-4/β-catenin complex, sub-
sequently contributing to tumorigenesis in hepatocellular
carcinoma (HCC). Similarly, SOX9 enhances tumor growth,
angiogenesis and invasion in prostate cancer. However,
SOX17 inhibits canonical Wnt/β-catenin signaling and sup-
presses tumor growth in papillary thyroid carcinoma. Con-
sistently, SOX1 is a tumor suppressor that is suppressed byhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ovarian cancers. These findings are in accordance with
the notion that hypermethylation of promoter regions
of tumor suppressor genes is a major contributor to car-
cinogenesis [15,16]. For example, hypermethylation of
the p16INK4a promoter leads to decreased expression
of its protein in NPC, further promoting tumorigenesis
[17,18]. Additionally, aberrant promoter methylation of
CDH13, DLEC1, CHFR and CDH1 has been implicated in
tumorigenesis [19,20]. However, whether the methylation
status of the SOX1 promoter is involved in the development
of NPC remains to be elucidated.
The canonical Wnt signaling pathway is involved in
various biological processes, including embryonic develop-
ment, cell proliferation and stem cell maintenance [21].
Moreover, the dysregulation of Wnt signaling is impli-
cated in human tumorigenesis. The central element of the
canonical Wnt pathway is β-catenin, which forms com-
plexes with TCF/lymphoid enhancer factor (LEF) HMG
box transcription factors to stimulate the transcription
of Wnt-responsive genes including CCND1, MYC and
Cdx-1 [22]. Previous studies have shown that SOX
family members regulate Wnt/β-catenin signaling through
interaction with β-catenin. For example, SOX7 can sup-
press expression of Cyclin D1 and c-Myc via direct inter-
action with β-catenin, thereby inhibiting Wnt/β-catenin
signaling in endometrial, prostate and colon cancers
[23,24]. Additionally, SOX1 competes with TCF/LEF by
physically binding to β-catenin and therefore interfering
with the activation of Wnt/β-catenin signaling in HCC
[25]. Therefore, we investigated whether SOX proteins
regulate Wnt/β-catenin signaling in NPC.
In this study, we demonstrate that depletion of SOX1
is responsible for the malignant phenotype of NPC. We
show that recovery of SOX1 expression leads to a down-
regulation of β-catenin that is independent of proteaso-
mal activity. These new data show that SOX1 decreases
β-catenin activity and reverses the malignant phenotype
of NPC.
Results
Down-regulation of SOX1 in NPC cells and tissues is
associated with promoter hypermethylation
We first examined the expression of SOX1 in six NPC
cell lines and found that both mRNA and protein were
barely detectable in all six cell lines. Conversely, both
SOX1 mRNA and protein were highly expressed in NP69
cells, an immortalized human normal nasopharyngeal epi-
thelial cell line (Figure 1A). We then confirmed these re-
sults in three primary NPC tissues and their corresponding
adjacent non-tumor tissues using quantitative real-time
polymerase chain reaction (qRT-PCR). SOX1 mRNA ex-
pression was significantly down-regulated in primary NPC
tissues when compared with the adjacent non-tumortissues (Figure 1B). We next asked whether the down-
regulation of SOX1 in NPC was caused by SOX1 pro-
moter methylation. We determined the methylation
status of the NPC cell lines by quantitative methylation-
specific PCR (qMS-PCR). Hypermethylation was con-
firmed in the NPC cell lines that showed down-regulated
SOX1 expression, whereas methylation was almost absent
in NP69 cells (Figure 1C). To determine whether pro-
moter methylation was involved in regulating SOX1, two
NPC cell lines (CNE2 and HONE1) were treated with
5-AZA-2′-deoxycytidine (5-Aza-CdR), a DNA methyl-
transferase inhibitor. Re-expression of SOX1 was detected
in both NPC cell lines when methylation was prevented
(Figure 1D). These data suggest that the low levels of SOX1
expression were attributable to promoter methylation.
Ectopic expression of SOX1 represses NPC cells proliferation
and migration
Since we observed a down-regulation of SOX1 in both
NPC cell lines and tissues, we next determined whether
overexpression of SOX1 could reverse the malignant
phenotype of NPC cells. Virus-mediated overexpression of
SOX1 in CNE2 and HONE1 cells was confirmed by western
blot (WB) and immunofluorescence (IF) analysis (Figure 2A).
Overexpression of SOX1 significantly decreased colony for-
mation and proliferation in both CNE2 and HONE1
cells (Figure 2B and C). SOX1 overexpression also sig-
nificantly decreased the percentage of Ki67 (+) cells in
both CNE2 and HONE1 cells (Figure 2D). Further-
more, we found that the migration ability of both
CNE2 and HONE1 cells was significantly suppressed
when SOX1 was overexpressed (Figure 2E, and F and
Additional file 1: Figure S1A).
SOX1 impairs tumor formation in a xenograft model
Next, we examined the influence of SOX1 on NPC cells
tumor formation in vivo. CNE2 cells stably transfected
with either empty vector or SOX1 were delivered subcuta-
neously into nude mice and tumor growth was monitored
(Figure 3A). The tumors were harvested and weighed after
20 days of growth. When compared with the control
group, the mean tumor volume (Figure 3B) and tumor
weight (Figure 3C) were significantly lower in mice in-
oculated with SOX1-overexpressing CNE2 cells. Tumor
volume decreased from 1165.30 ± 205.11 mm3 to 161.06 ±
58.03 mm3 and weight decreased from 1.15 ± 0.20 g to
0.15 ± 0.04 g (both p <0.001). These results suggest that
SOX1 impairs tumor growth in NPC cells in vivo.
SOX1 overexpression reduces epithelial-mesenchymal
transition, induces cell differentiation and enhances
cellular senescence
The functions of SOX1 in vitro were further investi-
gated by overexpressing SOX1 in either CNE2 or HONE1
Figure 1 Down-regulation of SOX1 in NPC cell lines and tissues is associated with promoter hypermethylation. (A) Endogenous protein level
(upper panel) and mRNA level (lower panel) of SOX1 were detected in NPC cell lines via WB and RT-PCR, respectively. (B) SOX1 transcripts of NPC
tissues (T) and their corresponding adjacent non-tumor tissues (N) were determined via qRT-PCR and normalized using GAPDH expression. Data
were analyzed via the ΔΔCt method and representative results from three samples (numbers 2, 3 and 23) are shown. Bar represents mean ± SD of
three independent experiments (***p <0.001, Student’s t test). (C) Methylation status of NPC cell lines was determined by qMS-PCR. M, methylated
SOX1; U, unmethylated SOX1. (D) NPC cell lines CNE2 and HONE1 were treated with or without 5 or 25 μM 5-Aza-CdR for 48 h. SOX1
transcripts were analyzed via qRT-PCR and normalized using GAPDH. Data were analyzed using the ΔΔCt method. Bar represents
mean ± SD of three independent experiments (**p <0.01, ANOVA followed by the least significant difference test was used to make
statistical comparisons).
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S2, overexpression of SOX1 down-regulated Vimentin and
up-regulated E-cadherin in HONE1 and CNE2 cells,
indicating that overexpression of SOX1 suppressed
epithelial-mesenchymal transition (EMT). HONE1 is
a poorly differentiated NPC cell line, and is histologically
characterized by a round and cobblestone-like phenotype.
Overexpression of SOX1 in HONE1 cells induced a
morphology transition to a slender and fusiform appear-
ance, which was defined as a differentiated phenotype
(Figure 4B). This phenotype was similar to those of the
well-differentiated NP69 and CNE1 cell lines [26]. Consistent
with these morphological changes, expressions of cell differ-
entiation markers such as Involucrin, CK8 and CK18 [27,28]
were increased, whereas undifferentiation markers such asCK19 and CK13 [29,30] were reduced (Figure 4B). Similar
results could be observed in the CNE2 cells (Additional file
1: Figure S1B and S1C). Taken together, these data indicated
that SOX1 overexpressing NPC cells were undergoing differ-
entiation. As SOX1 has been implicated in the regulation of
cell differentiation and EMT, we further examined the role
of SOX1 in stem cell regulation in NPC. We found that
sphere-forming ability was dramatically decreased by overex-
pression of SOX1 in both CNE2 (Additional file 3: Figure
S3A, p <0.01) and HONE1 (Additional file 3: Figure
S3B, p <0.01) cells. Meanwhile, colony-forming ability in
soft agar was also decreased in these cells (Additional file 3:
Figure S3C, both p <0.05). We also found that overexpres-
sion of SOX1 in HONE1 cells enhanced SA-β-gal staining
(Figure 4C).
Figure 2 Ectopic expression of SOX1 represses NPC cells proliferation and migration in vitro. (A) Ectopic expression of SOX1 in NPC cell
lines was confirmed by WB (GAPDH as internal control) and IF. (B, C, D) Colony formation assay, cell proliferation assay and Ki67 staining were
performed in NPC cells overexpressing SOX1. The colony formation ability reduced from 15.48 ± 3.29% to 4.90 ± 0.09% in CNE2 cells and from
11.14 ± 2.01% to 5.14 ± 0.82% in HONE1 cells. The Ki67 staining rate decreased from 0.54 ± 0.08 to 0.18 ± 0.05 in CNE2 cells and from 0.66 ±
0.11 to 0.29 ± 0.02 in HONE1 cells. Bar represents mean ± SD of three independent experiments (*p <0.05, **p <0.01, ***p <0.001, Student’s t test)
(E, F) Wound-healing assay and transwell migration assay were performed in NPC cells overexpressing SOX1. The transwell migration cell number for
each 20× field decreased from 64.33 ± 9.5 to 21.75 ± 2.99 in CNE2 cells and from 103.0 ± 18.2 to 27.0 ± 5.30 in HONE1 cells. Quantitative data are
shown as the mean ± SD from three independent experiments. (*p <0.05, **p <0.01, ***p <0.001, Student’s t test). (Scale bars, 50 μm in A, D, 100 μm
in E, F).
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capacity in SOX1 stably overexpressed NPC cells
To further demonstrate the anti-tumor function of SOX1,
we knocked down SOX1 with transient siRNA transfectionin CNE2 and HONE1 cells stably overexpressing SOX1.
We confirmed SOX1 expression in both cell lines via WB
(Figure 4D). Transient knockdown of SOX1 in these cells
partially rescued cell proliferation, demonstrated by the
Figure 3 SOX1 suppresses tumor formation in nude mice model. (A) CNE2 cells (1 × 106) virally transformed with vector-alone or SOX1
plasmid were injected into the left (vector-only) and right (SOX1) flank of nude mice, respectively (upper panel). Tumors were taken from mice of both
the control group and SOX1 overexpression group after 20 days (lower panel). (B) Tumor growth curve of SOX1-overexpressing cells compared with that
of vector-only cells. Points represent the mean tumor volumes of six independent experiments; bars represent the SD. (**p <0.01, ***p <0.001, Student’s
t test) (C) Tumor weight from the vector-only and SOX1 groups decreased from 1.15 ± 0.20 g to 0.15 ± 0.04 g. The results were obtained from
six independent experiments; bars represent the SD. (***p <0.001, Student’s t test).
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hanced colony formation ability (Figure 4F).
SOX1 interacts with β-catenin and induces a proteasome-
independent down-regulation of β-catenin
Previous studies have shown that SOX1 interacts with
β-catenin in vitro to suppress β-catenin-mediated TCF/LEF
signaling in HCC cell lines [25]. A co-immunoprecipitation
assay identified β-catenin and SOX1 in an immunocomplex
from HONE1 cell lysate, supporting the existence of this
interaction in NPC cell lines (Figure 5A). We also exam-
ined the cellular localization of SOX1 and β-catenin using
confocal microscopy, and identified SOX1 and β-catenin
co-localization in HONE1 cells (Figure 5B). Interestingly,
while expression of β-catenin was down-regulated in
SOX1-overexpressing HONE1 cells (Figure 5C), transcrip-
tion of the β-catenin gene was up-regulated (Figure 5D),
suggesting that SOX1 reduced expression of β-catenin at
the protein level. Furthermore, the down-regulation of
β-catenin induced by SOX1-overexpression was reversed
by knockdown of SOX1 using siRNA (Figure 5E). Consist-
ently, β-catenin was down-regulated in a dose-dependent
manner with increasing amounts of SOX1 (Figure 5F).
This phenomenon was not reversed by MG132, a spe-
cific proteasome inhibitor, suggesting that SOX1 down-
regulated β-catenin in a proteasome-independent manner
(Figure 5F).
SOX1 overexpression modulates the expression of cell
cycle-regulating proteins
To further explore the mechanisms by which SOX1 sup-
presses tumors, we measured the expression of downstreamtargets of Wnt/β-catenin in SOX1-overexpressing HONE1
cells. A decrease in both c-Myc and Cyclin D1 protein was
detected in SOX1-overexpressing HONE1 cells (Figure 6A).
To further investigate the influence of SOX1 overex-
pression on the cell cycle, we evaluated cell cycle progres-
sion by flow cytometry. Ectopic expression of SOX1
increased the number of cells in the G1/G0 phase
(from 67.77 ± 0.9% to 71.82 ± 1.05%) and decreased the
number of cells in the G2/M phase (from 12.7 ± 0.10%
to 9.3 ± 0.10%) in HONE1 cells (Figure 6B). To ascer-
tain how SOX1 inhibited cell growth, protein levels of
the cell cycle regulators p21, p27 and Cyclin E were
examined using WB. In HONE1 cells, SOX1 overex-
pression significantly enhanced the expression of p21
and p27 but suppressed the expression of Cyclin E
(Figure 6C).
Discussion
These new data provide compelling evidence to suggest
that SOX1 suppresses tumorigenicity and regulates ex-
pression of β-catenin in NPC. Both NPC cell lines and
NPC tissues showed decreased expression of SOX1 at
the mRNA and protein levels. Our data further indicate
that the decreased expression of SOX1 could be attrib-
uted to promoter hypermethylation. Moreover, overex-
pression of SOX1 in NPC cells reduced tumor formation
and the tumor burden in vivo. We also found that SOX1
induced NPC cell differentiation and reduced EMT.
Mechanistically, SOX1 inhibited the Wnt/β-catenin sig-
naling pathway by promoting β-catenin down-regulation
in a proteasome-independent manner. Our study there-
fore reveals a novel mechanism by which SOX1 regulates
Figure 4 (See legend on next page.)
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Figure 4 SOX1 reduces EMT, stimulates cell differentiation and triggers cellular senescence, whereas transient knockdown of SOX1
partially reverses the malignant phenotype. (A) Presence of the EMT-related proteins E-cadherin and Vimentin was detected via IF and WB. IF
(left panel) Blue, DAPI; Red, E-cadherin; Green, Vimentin. EMT-related markers were detected by WB (right panel) in HONE1 cells with forced SOX1
expression. GAPDH served as an internal control. (B) Morphology of differentiated HONE1 cells induced by SOX1 was observed under microscopy. WB
was used to detect the cell surface markers related to cell differentiation in HONE1 cells with or without SOX1 overexpression. (C) HONE1 cells with or
without SOX1 overexpression were fixed and stained for SA-β-gal activity. The number of senescent colonies within each 20× field of HONE1 cells
increased from 8.33 ± 1.53 to 50.33 ± 9.87. Bar represents mean ± SD of three independent experiments. (*p <0.05, Student’s t test) (D) SOX1
expression level in SOX1-overexpressing-NPC cells following transfection of SOX1-specific siRNA was determined using WB. (E, F) Ki67 staining rate
and colony formation ability following knockdown of SOX1 using siRNA in SOX1-overexpressing NPC cells. Ki67 staining rate increased from 0.17 ± 0.02
to 0.49 ± 0.10 in CNE2 cells and from 0.14 ± 0.02 to 0.28 ± 0.06 in HONE1 cells. Colony formation ability increased from 6.82 ± 1.77% to 15.47 ± 5.28% in
HONE1 cells. Bar represents mean ± SD of three independent experiments (*p <0.05, **p <0.01, Student’s t test). (Scale bars, 50 μm in A, 25 μm
in B, C, 50 μm in E).
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in NPC.
A previous study has shown that another member of
the SOX family, SOX11, can also act as a tumor sup-
pressor in NPC cells. Down-regulation of SOX11 mRNA
expression was observed in NPC tissues that displayed
methylation of SOX11 promoters. CNE2 cells treated
with the hypomethylating agent 5-Aza-CdR recovered
expression of SOX11 and experienced inhibited cell growth
and invasion [31]. Consistently, we found that SOX1 was
also down-regulated via promoter hypermethylation in
NPC (Figure 1C and D). Overexpression of SOX1 subse-
quently decreased expression of β-catenin and suppressed
the Wnt/β-catenin signaling pathway, thereby reversing
the malignant phenotype of NPC cells. Our findings sug-
gest that an inhibitor of promoter hypermethylation that
specifically targets tumor suppressor genes could be bene-
ficial for future NPC treatment strategies.
Functional analysis of the SOX family as transcription
factors has demonstrated their important roles in stem
cell regulation [8]. These discoveries have linked SOX
family proteins with Wnt/β-catenin-mediated regulation
of stem cell self-renewal and differentiation [21]. For in-
stance, SOX3 and SOX17 were first reported to regulate
the canonical Wnt/β-catenin signaling pathway in Xen-
opus embryos [32]. More recently, the link between SOX
family proteins and Wnt/β-catenin signaling has been
implicated in tumorigenesis [14,23]. For example, SOX7
and SOX17 have been suggested to suppress tumor
growth through an interaction with β-catenin in various
cancer types. Furthermore, overexpression of SOX1
attenuated β-catenin-mediated TCF/LEF signaling via
binding with β-catenin and competition for TCF/LEF
binding sites in HCC [25].
Previous reports showed that SOX1 acted as a tumor
suppressor by interacting with β-catenin in cervical and
liver cancers [25,33]. SOX1 interfered with Wnt/β-catenin
signaling by competing for TCF/LEF binding sites in HCC.
Consistently, our results demonstrate that SOX1 can sup-
press malignant properties and induce decreased expres-
sion of β-catenin in NPC (Figures 2, 3, 4 and 5C). In thecanonical Wnt/β-catenin signaling pathway, β-catenin deg-
radation occurs predominantly through a multiprotein
destruction complex comprising factors including tumor
suppressors adenomatous polyposis coli (APC), Axin, the
kinases casein kinase 1 (CK1) and glycogen synthase
kinase 3β (GSK-3β). APC recruits β-catenin to the destruc-
tion complex, where it is phosphorylated at N-terminal
serine and threonine residues by CK1 and GSK-3β, leading
to its ubiquitination and subsequent proteasomal degrad-
ation [34]. In the present study, we found that levels of
β-catenin protein, but not mRNA, were down-regulated
by SOX1 overexpression in a dose-dependent manner
(Figure 5F). Furthermore, the down-regulation of β-catenin
induced by SOX1 could not be reversed by MG132, sug-
gesting that SOX1 promoted the down-regulation of
β-catenin through a proteasome-independent pathway.
We also found that SOX1 and β-catenin were present in
the same immunocomplex and also co-localized in
HONE1 cells (Figure 5A and B). The co-localization of
SOX1 and β-catenin partially overlaps with the nuclear
DNA signal, suggesting that the co-localization may
reside in the cytoplasm and that SOX1 can induce
down-regulation of β-catenin in the cytoplasm. These
results are consistent with previous reports that β-catenin
is degraded in the cytoplasm. Here, we have shown for the
first time that SOX proteins can attenuate Wnt/β-catenin
signaling independent of the proteasome pathway, and
will further investigate the mechanism(s) underlying this
SOX1-mediated β-catenin down-regulation in future
studies.
Dysregulation of the cell cycle contributes to the eti-
ology of several diseases, including cancer. It has been well
established that the Wnt/β-catenin signaling pathway is
involved in cell cycle regulation in various cancers [21,35].
Moreover, as downstream targets of the Wnt/β-catenin
signaling pathway, Cyclin D1 and c-Myc play important
roles in cell cycle regulation. We found that overexpres-
sion of SOX1 decreased β-catenin in NPC cells, and that
down-regulation of Cyclin D1 and c-Myc as well as
up-regulation of p21 and p27 also occurred in SOX1-
overexpressing HONE1 cells (Figure 6A and C).
Figure 5 SOX1 suppresses Wnt/β-catenin signaling by interacting with β-catenin and stimulating its down-regulation in a proteasome-
independent manner. (A) IP was performed on whole-cell lysate from HONE1cells expressing SOX1-myc using an anti-myc-tag antibody. The
same amount of mouse immunoglobulin G and blank (empty) were used as negative controls. Immunoprecipitated protein complexes were analyzed
by WB to detect β-catenin and SOX1 with myc-tag. (B) Merged images depicting co-localization of SOX1 and β-catenin by laser confocal microscopy.
Blue, DAPI; Red, SOX1; Green, β-catenin. (Scale bar, 20 μm in B) (C, D) The SOX1 and β-catenin protein and mRNA levels of HONE1 cells with or without
SOX1 overexpression were detected via WB (C) and qRT-PCR (D), (**p <0.01, ***p <0.001, Student’s t test). (E) SOX1-overexpressing HONE1 cells
were transfected with mock and SOX1 siRNA. SOX1 and β-catenin expression were determined by WB. (F) Expression of SOX1 and β-catenin
were determined by WB in HONE1 cells transfected with 0, 0.5, 1, or 2 μg of the SOX1 plasmid either with or without the addition of 20 μg/ml MG132
for 12 h. GAPDH was used as an internal control.
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creased the number of cells in the G1/G0 phase while de-
creasing the number of cells in the G2/M phase
(Figure 6B). These results suggested that SOX1 inhib-
ited cell cycle progression by attenuating Wnt/β-catenin
signaling. Additional evidence of this is supplied by studies
of neural system development, where SOX1 binding to β-
catenin suppressed β-catenin-mediated TCF/LEF signal-
ing, thereby promoting cell cycle exit [36]. Further studiesare needed to investigate the mechanism involved in the
cell cycle regulation by SOX1.
Previous reports have demonstrated that SOX1 regu-
lates the differentiation of neural progenitor cells by
directly binding to β-catenin and suppressing β-catenin-
mediated TCF/LEF signaling [36,37]. These reports are
consistent with our finding that overexpression of SOX1
triggers differentiation of CNE2 and HONE1 cells, which
are both poorly differentiated NPC cell lines (Figure 4B
Figure 6 SOX1 inhibits Wnt/β-catenin downstream genes and modulates the expression of molecules involved in the cell cycle. (A)WB for
expression of c-Myc and Cyclin D1 in SOX1-overexpressing HONE1 cells. (B) Flow cytometry cell cycle analysis of HONE1 cells overexpressing SOX1.
The percentage of cells in G1 phase increased from 67.77 ± 0.9% to 71.82 ± 1.05% while the percentage of cells in G2/M phase decreased from
12.7 ± 0.10% to 9.3 ± 0.10% in HONE1 cells overexpressing SOX1. Bar represents mean ± SD of three independent experiments. (*p <0.05,
Student’s t test). (C) Proteins involved in the cell cycle after SOX1 expression was forced in HONE1 cells were identified via WB. GAPDH was
used as an internal control.
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tigation is needed to explore how SOX1 regulates cancer
cell differentiation and whether the interaction between
SOX1 and β-catenin is involved in this regulation. Our
findings will provide new guidance for NPC treatment
and improve prognoses in the future.Conclusion
SOX1 expression is frequently down-regulated in NPC
because of promoter hypermethylation. Overexpression
of SOX1 reverses the malignant phenotype of NPC cells
by suppressing cell migration and EMT and inducing cell
senescence and cell differentiation. The potential mech-
anism by which SOX1 suppresses Wnt/β-catenin signal-
ing is by down-regulation of β-catenin and subsequent
inhibition of downstream gene expression. These find-
ings indicate that SOX1 plays a pivotal role as a tumor
suppressor in NPC development.Methods
Cell lines and cell culture
Six NPC cell lines (CNE1, CNE2, HONE1, SUNE1, 58 F
and HK1) and an immortalized normal nasopharyngeal
epithelial cell line (NP69) were used in this study. All
cells were obtained from the State Key Laboratory of
Oncology in South China. CNE1 and CNE2 were cultured
in RPMI-1640 (Gibco, Life Technologies, CA, USA)
containing 10% fetal calf serum (Gibco). HONE1, SUNE1,
58 F and HK1 were cultured in RPMI-1640 containing 10%
fetal bovine serum (Hyclone, South America). NP69 cells
were propagated in defined keratinocyte-serum-free medium
(K-SFM; Gibco, Life Technologies, Basel, Switzerland)
supplemented with growth factors. Virus-converted cells
with and without stable SOX1 overexpression (CNE2-
pLVPT and CNE2-SOX1, HONE1-pLVPT and HONE1-
SOX1) were maintained in incomplete medium with1.5 μg/ml puromycin. All cells were maintained at 37°C
in a humidified atmosphere containing 5% CO2.
Bisulfite conversion and quantitative methylation-specific
polymerase chain reaction (qMS-PCR)
qMS-PCR was performed using the EZ DNA Methylation-
Gold™ Kit (ZYMO Research, CA, USA) according to the
manufacturer’s protocol. The primer sequence for qMS-
PCR has been described [38]. Methylated primers for each
construct were as follows: hSOX1, forward 5′-CGTTT
TTTTTTTTTCGTTATTGGC-3′, reverse 5′-CCTACGC
TCGATCCTCAACG-3′; unmethylated primers for hSOX1,
forward 5′-TGTTTTTTTTTTTTTGTTATTGGTG-3′, re-
verse 5′-CCTACACTCAATCCTCAACAAC-3′. All qMS-
PCR data were obtained from at least three independent
experiments to ensure reproducibility.
RNA isolation, reverse-transcription PCR (RT-PCR) and
real-time quantitative RT-PCR
RNA was isolated from each tissue or cell sample using
Trizol reagent (Invitrogen, CA, USA) according to the
manufacturer’s protocol. A 2-μg aliquot of total RNA
from each sample was used for cDNA synthesis with
SuperScript® III RT (Invitrogen) and an oligo-dT primer.
PCR was performed at 95°C for 5 min, then 30 cycles
(95°C for 5 sec, 55–68°C for 15 sec and 72°C for 1 min)
with a final extension of 10 min at 72°C. The primer se-
quence for SOX1 was as follows: forward 5′-AAGGT
GAAGGTCGGAGTCAAC-3′, reverse 5′-GGGGTCAT
TGATGGCAACAATA-3′. Real-time PCR was performed
using Platinum® SYBR® Green qPCR SuperMix (Invitrogen)
and analyzed on a CFX96 Real-Time System (Bio-Rad, CA,
USA). Glyceraldehyde-3-phosphate dehydrogenase gene
(GAPDH) was used as an internal control. The difference
of real-time PCR cycle number (Ct value) between the tar-
get gene and GAPDH was quantified using the ΔΔCT
method.
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The WB procedure was performed as described previ-
ously [39] with some modifications. Briefly, after transi-
ent transfection with plasmids, cells were harvested and
lysed in a lysis buffer containing a cocktail of protease
inhibitors. After centrifugation at 12,000 rpm for 15 min
at 4°C, supernatants were collected, mixed with dithio-
threitol, and used for WB. The ProteoExtract® Subcellular
Proteome Extraction Kit (Millipore) was used for extrac-
tion of subcellular fractions following the manufacturer’s
protocol. Equal amounts of protein extract were electro-
phoresed in 10% SDS-PAGE gels and then transferred to
nitrocellulose membranes. The membranes were blocked
with 5% bovine serum albumin (BSA) at room temperature
(RT) for 1 h, incubated with the primary antibody
overnight at 4°C, and incubated with the secondary
antibody at room temperature for 1 h. Blots were
washed in Tris-buffered saline with 0.1% Tween-20
and proteins were visualized by chemiluminescence.
The following antibodies were used for WB: anti-SOX1 (IB
1:2000, Epitomics, CA, USA), anti-CK19 (1:8000, Epi-
tomics), anti-CK18 (1:4000, Epitomics), anti-CK13 (1:4000,
Epitomics), anti-CK8 (1:4000, Epitomics), anti-Involucrin
(1:4000, Abcam, MA, USA), anti-GAPDH (1:10000, Pro-
teinTec Group, IL, USA), anti-c-Myc (N-262) (1:2000,
Santa Cruz Biotechnology, CA, USA), and anti-β-catenin
(1:2000, Upstate, NY, USA).
Immunofluorescence (IF)
The IF procedure was performed as described previously
[40] with some modifications. Briefly, cells were seeded
on slides at 50% confluency in 6-well plates for 24 h be-
fore fixation. All the following procedures were per-
formed at room temperature. Cells on slides were fixed
with 2% formalin for 15 min. After rinsing with phosphate-
buffered saline (PBS), slides were permeabilized in 0.25%
Triton-X-100 buffer for 15 min. After rinsing with PBS,
non-specific sites on the slides were blocked with 3% BSA
for 20 min. Slides were then incubated with primary
antibodies diluted in 3% BSA for 1 h: anti-SOX1 (1:200),
β-catenin (1:200), Ki67 (1:200, Santa Cruz Biotechnology).
After rinsing with PBS, the slides were incubated with sec-
ondary antibody (1:200) for 1 h in the dark. The slides
were rinsed with PBS, stained with 100 ng/ml 4′,6-diami-
dino-2-phenylindole for 5 min, and rinsed with PBS. The
slides were dried and placed on embedding medium on
cover slides, and then observed under a fluorescence
microscope.
Immunoprecipitation
Immunoprecipitation was conducted according to a previ-
ous report [26]. Polyclonal Anti-c-myc-tag (Sigma-Aldrich,
MO, USA) antibody was cross-linked to protein G beads
(Invitrogen) according to the manufacturer’s protocol. Celllysate from NPC cells transfected with SOX1-myc plasmid
was pre-cleared with IgG beads-protein G for 2 h and then
incubated with c-myc-tag-beads overnight at 4°C. C-myc-
tag-immunoprecipitated complexes were washed five times
with immunoprecipitation buffer (10 mM Tris/HCl,
pH 7.8; 1 mM EDTA; 150 mM NaCl; 1 mM NaF; 0.5%
Nonidet P-40; 0.5% glucopyranoside; 1 μg/ml aproti-
nin; and 0.5 mM phenylmethylsulfonyl fluoride). Pro-
teins were eluted from beads by boiling in loading
buffer, and then subjected to WB. Anti-β-catenin and
anti-c-myc-tag antibodies were used to detect β-catenin
and SOX1-myc.
Colony formation assay
The colony formation assay was performed according to
the procedure reported previously [41]. Briefly, cells were
trypsinized, resuspended as single cells and plated onto
6-well plates with 500 cells per well. After 10 days, the
colonies were fixed with 2% methanol and stained with
crystal violet. Colonies with more than 50 cells were
counted under the microscope. The cloning efficiency
was calculated using the whole area of the colonies.
Wound-healing assay and transwell migration assay
For the wound-healing assay, CNE2-EV&SOX1 and
HONE1-EV&SOX1 cells were seeded in a 6-well plate
at 90% confluence. The day before the assay, cells were
starved with serum-free medium overnight. A sterile
200-μl pipet tip was used to scratch three separate
wounds through the cells moving perpendicular to the
line drawn with a marker on the bottom of the dish.
Then, cells were gently rinsed with PBS and 1.5 ml of
media was added. Pictures were taken using a phase
contrast microscope at 0, 12, 16 and 20 h. For the transwell
migration assay, 800 μl of normal medium was added to the
lower chamber in a 24-well plate, and 200 μl cell suspension
(1 × 105 cells) in SFM was added to the upper chamber.
After incubation for 24 h (37°C, 5% CO2), the membrane
was fixed with 2% methanol and stained with crystal violet.
Pictures were taken under a microscope and the stained
cells in the lower side of the membrane were counted.
In vivo tumorigenicity
CNE2 cells (5 × 105) transfected with empty vector or
SOX1-expressing plasmid were injected subcutane-
ously into the left and right flanks of 6-week-old nude
mice (Guangdong Medical Laboratory Animal Center,
Guangdong, China). The tumor volume was calculated
as 0.5 × L1 × (L2)2, where L1 is the long axis and L2 is
the short axis of the tumor. The developing tumors
were observed every third day. After 20 days, the mice
were sacrificed at the end of follow-up. The animal
study protocol was approved by the Institutional Animal
Care and Use Committee.
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CNE2-EV&SOX1 and HONE1-EV&SOX1 cells were plated
in a 6-well plate. The Senescence-β-Gal Staining Kit (Beyo-
time Institute of Biotechnology, Jiangsu, China) was used ac-
cording to the manufacturer’s instructions. Briefly, cells were
fixed with fixation buffer for 10 min after rinsing three times
in PBS for 5 min at RT. The cells were stained with staining
buffer at 37°C overnight covered with plastic wrap. The cells
were rinsed three times in PBS for 5 min at RT and
observed under a microscope.
Flow cytometry for cell cycle analyses
Cells were harvested by digestion, washed with pre-chilled
PBS, fixed with 70% ethanol at 4°C for 30 min, then
stained with propidium iodide (Sigma-Aldrich, 50 mg/ml)
for 30 min at 4°C in the dark. Stained cells were subjected
to flow cytometry analysis to measure the sub-G1 fraction.
Sphere formation assay
Sphere formation assays were performed as per a pre-
vious report [42]. Cells were seeded into an ultralow
attachment 24-well plate (Corning) at 500 cells per well.
Cells were grown in a DMEM/F12 medium (Gibco),
supplemented with B27 (Invitrogen), EGF (20 ng/ml),
bFGF (20 ng/ml, BD Biosciences), and heparin (0.5 U/ml,
Sigma). Fresh medium was added (200 μl/well) and the
plates were gently shaken every other day. Spheres were
counted following 10–15 days of culture.
Soft agar colony formation assay
Soft agar colony formation assays were conducted accord-
ing to a previous report [43]. Briefly, cells were resus-
pended in medium containing 0.6% agarose (500 cells/well)
and seeded into a 6-well plate coated with 1.2% agarose.
Then 2 ml culture medium was added on the top to
maintain moisture and nutrient availability. Colonies
were counted after culture for 2–3 weeks.
Statistical analysis
Statistical analyses were performed using the SPSS soft-
ware, version 16.0 (SPSS Inc.) or with GraphPad Prism
5.0 (GraphPad Software, Inc.). The unpaired Student’s t
test was used to perform a statistical comparison be-
tween two groups. The ANOVA test was used when per-
forming multiple comparisons. The level of significance
was set at p <0.05. Error bars represent the standard de-
viation of the mean (SD), and each experiment was com-
pleted at least twice with samples in triplicate.
Additional files
Additional file 1: Figure S1. Ectopic expression of SOX1 represses CNE2
cells migration and induces cell differentiation in vitro. (A) The wound-healing
assay performed in CNE2 cells overexpressing SOX1. (B) Morphology ofdifferentiated CNE2 cells induced by SOX1 was observed under microscopy.
(C) WB was used to detect the cell surface markers related to cell
differentiation in CNE2 cells with or without SOX1 overexpression.
(Scale bars, 200 μm in A and 25 μm in B).
Additional file 2: Figure S2. SOX1 reduces epithelial–mesenchymal
transition in CNE2 cells. (A) Presence of the EMT-related proteins E-cadherin
and Vimentin were detected via IF in CNE2 cells. Blue, DAPI; Red, E-cadherin;
Green, Vimentin. (B) EMT-related markers were detected by WB in CNE2 cells
with forced SOX1 expression. GAPDH served as an internal control.
Additional file 3: Figure S3. Overexpression of SOX1 negative
regulated the stem cell ability of NPC cells. (A, B) The sphere formation
ability reduced significantly in both CNE2 (from 64.5 ± 9.95 to 32 ± 10.23
per 500 cells, **p < 0.01, Student’s t test) and HONE1 (from 31.25 ± 5.12
to 12.75 ± 3.50 per 500 cells, **p < 0.01). (C) The colony formation ability
in soft agar dramatically decreased upon SOX1 overexpression, from 19.3 ±
4.5 to 5.3 ± 1.5 each 20× field in CNE2 and from 20.7 ± 5.0 to 7.7 ± 2.1 each
20× field in HONE1, both *p < 0.05, Student’s t test. Quantitative data were
shown as the mean ± SD from three independent experiments. (Scale bars,
100 μm in A, B, 1000 μm in C).
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